GU Cancers 2025 | Phase Ib/II trial of 177Lu-Girentuximab, cabozantinib and nivolumab in aRCC
Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of a phase Ib/II study (NCT05663710) assessing 177Lu-Girentuximab with cabozantinib and nivolumab in treatment-naïve advanced clear cell renal cell carcinoma (aRCC). By leveraging targeted radiation to enhance T cell activity, this approach aims to improve complete response rates beyond current immunotherapy standards. Primary and secondary endpoints include response rates, progression-free survival, and overall survival. The study incorporates advanced imaging and molecular analyses to evaluate treatment-induced immune activation. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
